查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球下呼吸道疾病診斷和治療市場
市場調查報告書
商品編碼
1327652

2023-2030年全球下呼吸道疾病診斷和治療市場

Global Lower Respiratory Tract Disease Diagnosis and Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

預計全球下呼吸道疾病診斷和治療市場在預測期內（2023-2030年）將以7.4%的年複合成長率成長。下呼吸道疾病診斷和治療市場的促進因素包括下呼吸道疾病發病率上升、人口老齡化、意識和診斷的提高、政府舉措和醫療政策、環境變量（如空氣污染、氣候變化和過敏原） ，以及技術創新。由於全球多個國家的空氣品質日益惡化，導致感冒、咳嗽和過敏的發病率增加。因此，有多項舉措旨在改善空氣品質指數（AQI），同時提供高效的醫療設施來治療此類感染。例如，2023 年 3 月，倫敦超低排放區（ULEZ）項目採用移動空氣品質監測技術來追踪空氣品質，計劃到 2050 年減少 100 萬人住院治療。被污染的空氣。

細分市場前景

全球下呼吸道疾病診斷和治療市場按病情、診斷、治療和類別細分。根據情況，市場分為肺炎、支氣管炎、肺結核和其他（流感）。根據診斷，市場細分為粘液樣本、血液測試、胸部 X 光檢查和脈搏血氧測定。根據治療方法，市場細分為非類固醇抗發炎藥、鎮痛藥和退燒藥、支氣管擴張吸入器和其他藥物（抗生素）。此外，根據類別，市場分為非處方藥和處方藥。在這些疾病中，由於支氣管炎病例患病率的上升以及治療支氣管炎的新的和更有效的藥物的開發的增加，預計支氣管炎細分市場將佔據相當大的市場佔有率。

預計支氣管擴張吸入器細分市場將佔據相當大的市場佔有率

其中，支氣管擴張吸入器細分市場預計將在全球下呼吸道疾病診斷和治療市場中佔據相當大的佔有率。細分市場的成長歸因於聯合療法日益成長的影響力。結合兩種或多種支氣管擴張吸入劑藥物的聯合療法變得越來越普遍，因為它們提供更好的治療效果並且對患者來說更方便。例如，2020 年8 月，Teva Pharmaceutical Industries Ltd. 推出了ProAir (R) Digihaler (R)（硫酸沙丁胺醇117 mcg）吸入粉，這是第一個也是唯一一個被批准用於4 歲及以上患者的數位救援吸入器。該吸入器用於治療和預防可逆性阻塞性氣道疾病患者的支氣管痙攣，以及避免運動誘發的支氣管痙攣 (EIB)。

區域展望

全球下呼吸道疾病診斷和治療市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於亞太地區人口不健康的生活方式，預計該地區將在全球市場中佔據顯著佔有率。擴大醫療基礎設施和提高患者意識是推動區域市場成長的另一個因素。

北美全球下呼吸道疾病診斷和治療市場預計將以顯著的年複合成長率成長

在所有地區中，預計北美地區在預測期內將以顯著的年複合成長率成長。不斷成長的老年人口、免疫力低下的老年人和兒童的多重耐藥細菌感染是促進該地區市場成長的一些因素。哮喘、慢性阻塞性肺病、肺炎和支氣管炎等下呼吸道疾病給全球醫療保健系統帶來了沉重負擔。因此，這些疾病的日益流行將推動對下呼吸道疾病診斷和治療的需求。據美國肺臟協會 (ALA) 稱，約有 1000 萬美國人因吸煙而患有急性支氣管炎。因此，非營利性政府組織 (NGO) 與私人和政府機構合作，推出了各種活動和計劃，以提高美國民眾的認知。例如，2023 年 5 月，Grifols 在美國推出了首個免費的直接面對消費者的計劃，以篩查 COPD 的遺傳風險。該計劃由一家生產血漿衍生藥物和創新診斷技術的公司推出。該計劃被命名為 AlphaID At Home。

市場參與者展望

服務於下呼吸道疾病診斷和治療市場的主要公司包括：艾伯維公司、葛蘭素史克公司、強生公司。有限公司、默克公司、諾華公司、武田製藥有限公司等。市場參與者通過採取各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2022 年 4 月，輝瑞公司和 ReViral Ltd. 簽訂了一項具有約束力的協議，根據協議，輝瑞以 5.25 億美元的價格收購了 ReViral。通過此次收購，輝瑞旨在加強其傳染病研發能力並增強其對呼吸道合胞病毒的治療。

報告涵蓋：

  • 2022年市場價值數據分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球下呼吸道疾病診斷和治療市場的主要公司。根據現有數據，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 通過確定未來強勁成長的關鍵細分市場來分析業務戰略。
  • 市場進入和市場擴張策略分析。
  • 通過識別市場中“誰的立場”來製定競爭策略。

目錄

第 1 章：報告摘要

  • 當前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章：市場概述和見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Pfizer Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Teva Pharmaceutical Industries Ltd.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 全球下呼吸道疾病分病診治
    • 肺炎
    • 支氣管炎
    • 結核病 (TB)
    • 其他（流感）
  • 全球下呼吸道疾病的診斷治療
    • 粘液樣本
    • 血液檢查
    • 胸部 X 光檢查
    • 脈搏血氧儀
  • 全球下呼吸道疾病的治療診斷
    • 非類固醇類抗發炎藥 (NSAID)
    • 鎮痛解熱藥
    • 支氣管擴張吸入器
    • 其他（抗生素）
  • 全球下呼吸道疾病分類診斷
    • 場外交易 (OTC)
    • 處方

第 5 章：區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca
  • Aurobindo Pharma
  • Bristol Myers Squibb's
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Private Limited
  • Lupin
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • SHIONOGI & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Ltd.
Product Code: OMR2027540

Title: Global Lower Respiratory Tract Disease Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Condition (Pneumonia, Bronchitis, Tuberculosis, and Others), by Diagnosis (Mucus Samples, Blood Tests, Chest X-Rays, and Pulse Oximetry), and by Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Analgesics and, Antipyretic Drugs, Bronchodilator Inhaler and Others), and by Category (Over-the-Counter (OTC) and Prescription),Forecast Period (2023-2030).

The global lower respiratory tract disease diagnosis and treatment market is anticipated to grow at a CAGR of 7.4% during the forecast period (2023-2030). The lower respiratory tract disease diagnosis and treatment market is driven by the rising incidence of lower respiratory tract diseases, the aging population, increased awareness and diagnosis, government initiatives and healthcare policies, environmental variables (such as air pollution, climate change, and allergens), and innovations in technology. Owing to the day-by-day degrading air quality of several nations around the globe has propelled the incidence of cold, cough, and allergies. Hence, there were several initiatives witnessed aiming to improve the air quality index (AQI) while providing well-efficient healthcare facilities for the treatment of such infections. For instance, in March 2023, the ultra-low emission zones (ULEZ) project in London employed mobile air quality monitoring technology to track air quality and intends to cut one million hospital admissions by 2050. It tries to prevent lower respiratory tract problems brought on by polluted air.

Segmental Outlook

The global lower respiratory tract disease diagnosis and treatment market is segmented by condition, diagnosis, treatment, and category. Based on the conditions, the market is sub-segmented into pneumonia, bronchitis, tuberculosis, and others (influenza). Based on the diagnosis, the market is sub-segmented into mucus samples, blood tests, chest X-rays, and pulse oximetry. Based on the treatment, the market is sub-segmented into NSAIDs, analgesics and antipyretics, bronchodilator inhalers, and others (antibiotics). Further, on the basis of category, the market is bifurcated into OTC and prescription. Among the conditions, the bronchitis sub-segment is anticipated to hold a considerable share of the market owing to the rise in prevalence of bronchitis cases coupled with the rise in development of new and more effective medications treating bronchitis.

The Bronchodilator Inhaler Sub-Segment is Anticipated to Hold a Considerable Share of the Market

Among the treatments, the bronchodilator inhaler sub-segment is expected to hold a considerable share of the global lower respiratory tract disease diagnosis and treatment market. The segmental growth is attributed to the growing influence of combination therapies. Combination therapies, which combine two or more bronchodilator inhaler medications, are becoming increasingly common as they provide better therapeutic results and are more convenient for patients. For instance, in August 2020, Teva Pharmaceutical Industries Ltd. introduced ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler approved for use in patients aged 4 years and above. The inhaler is used to treat and prevention bronchospasm in those with reversible obstructive airway disease, as well as for the avoidance of exercise-induced bronchospasm (EIB).

Regional Outlook

The global lower respiratory tract disease diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the unhealthy lifestyles of the regional population. Expanding the healthcare infrastructure and increasing patient awareness are another factor to boost the regional market growth.

North America is Expected to Grow at a Significant CAGR in the Global Lower Respiratory Tract Disease Diagnosis and Treatment Market

Among all regions, the North America is anticipated to grow at a significant CAGR over the forecast period. Growing geriatric populations, immune-compromised seniors, and multi-drug resistant bacterial infections in children are some factors contributing to the region's market growth. Lower respiratory tract diseases, such as asthma, COPD, pneumonia, and bronchitis, among others, imposes a significant burden on global healthcare systems. Hence, the growing prevalence of these diseases will propel the demand for lower respiratory tract diseases diagnosis and treatments. According to the American Lung Association (ALA), around 10 million Americans are suffering from acute bronchitis, owing to the smoking. Resultantly, the non-profit government organization (NGOs) in collaboration with private and government institutions are introducing various campaigns and programmes creating awareness among the population in the US. For instance, in May 2023, Grifols, introduced first-ever free direct-to-consumer program in the US to screen for the genetic risk of COPD. The programme was unveiled by a company that produces plasma-derived medications and innovative diagnostic technologies. The initiative is named as AlphaID At Home.

Market Players Outlook

The major companies serving the lower respiratory tract disease diagnosis and treatment market include: AbbVie Inc., GlaxoSmithKline plc, Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Novartis AG, Takeda Pharmaceutical Company Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Pfizer Inc. and ReViral Ltd. entered into a binding agreement under which Pfizer acquired ReViral for worth $525 million. Through this acquisition, Pfizer aims to strengthen its infectious diseases R&D capabilities and enhance its treatment of RSVs.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global lower respiratory tract disease diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Pfizer Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Pharmaceutical Industries Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Lower Respiratory Tract Disease Diagnosis and Treatment by Condition
    • 4.1.1. Pneumonia
    • 4.1.2. Bronchitis
    • 4.1.3. Tuberculosis (TB)
    • 4.1.4. Others (Influenza)
  • 4.2. Global Lower Respiratory Tract Disease Treatment by Diagnosis
    • 4.2.1. Mucus Samples
    • 4.2.2. Blood Tests
    • 4.2.3. Chest X-Rays
    • 4.2.4. Pulse Oximetry
  • 4.3. Global Lower Respiratory Tract Disease Diagnosis by Treatment
    • 4.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 4.3.2. Analgesics and Antipyretic Drugs
    • 4.3.3. Bronchodilator Inhalers
    • 4.3.4. Others (Antibiotics)
  • 4.4. Global Lower Respiratory Tract Disease Diagnosis by Category
    • 4.4.1. Over-the-Counter (OTC)
    • 4.4.2. Prescription

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories
  • 6.2. AbbVie Inc.
  • 6.3. AstraZeneca
  • 6.4. Aurobindo Pharma
  • 6.5. Bristol Myers Squibb's
  • 6.6. GlaxoSmithKline plc
  • 6.7. Hikma Pharmaceuticals PLC
  • 6.8. Johnson & Johnson Private Limited
  • 6.9. Lupin
  • 6.10. Merck & Co., Inc.
  • 6.11. Novartis AG
  • 6.12. Sanofi
  • 6.13. SHIONOGI & Co., Ltd.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Takeda Pharmaceutical Company Ltd.

LIST OF TABLES

  • 1. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 2. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR PNEUMONIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR BRONCHITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR TB MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR OTHER CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY MUCUS SAMPLES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY BLOOD TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY CHEST X-RAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY PULSE OXIMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL LOWER RESPIRATORY TRACT DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 12. GLOBAL NSAIDS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL ANALGESICS AND ANTIPYRETIC DRUGS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BRONCHODILATOR INHALER FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL OTHER TREATMENTS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 17. GLOBAL OTC FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL PRESCRIPTION FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 25. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 27. EUROPEAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 28. EUROPEAN LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 29. EUROPEAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 33. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 34. ASIA- PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 38. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 39. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CONDITION, 2022 VS 2030 (%)
  • 2. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR PNEUMONIA MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR BRONCHITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR TB MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT FOR OTHER CONDITIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL LOWER RESPIRATORY TRACT DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022 VS 2030 (%)
  • 7. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY MUCUS SAMPLES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY BLOOD TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY CHEST X-RAYS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT BY PULSE OXIMETRY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022 VS 2030 (%)
  • 12. GLOBAL NSAIDS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ANALGESICS AND ANTIPYRETIC DRUGS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BRONCHODILATOR INHALER FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL OTHER TREATMENTS FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY CATEGORY, 2022-2030 ($ MILLION)
  • 17. GLOBAL OTC FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL PRESCRIPTION FOR LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. US LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD LOWER RESPIRATORY TRACT DISEASE DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)